PDAB Posted in the Assembly Financial Institutions
and Insurance Committee
A-1747/S-329, legislation to create a Prescription Drug Affordability Board, has been posted in the Assembly Financial Institutions and Insurance Committee for this Thursday, February 3. BioNJ believes a Prescription Drug Affordability Board is the wrong way to address Patient out-of-pocket costs. Rather than taking a systemwide, holistic approach that addresses the drug supply chain middlemen, co-insurance, co-payments and health benefit design issues that can have the biggest impact on Patient costs, PDABs focus squarely on the innovative biopharmaceutical sector without any guarantee of Patient savings on necessary and lifesaving prescription treatments.
Click here for BioNJ’s whitepaper which demystifies
some of the myths commonly used in support of Prescription Drug Affordability Board proposals. We hope you will stand with us and the Patients we serve in opposition of the Prescription Drug Affordability Board proposal. Click here to send a letter to your legislator now. Tell them to oppose A-1747/S-329.